I missed the eye papers by Sinclair and in fact, he has 2 papers published last year. We do not know if ATH434 will activate Sirtuins but that is what I believe is happening. IMO, without sirtuin activation, the animal studies would not demonstrate so good results as we have seen in the 2 ATH434 papers published, most clearly the paper by Stefanova et al last July in the MSA animal model. As you may remember sirtuin activation needs NAD+. In the first paper below NAD+ precursor, NMN demonstrated a neuroprotective effect.
Here are the 2 papers by Sinclair et al.
Aging | Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment - Full Text (aging-us.com)
Reprogramming to recover youthful epigenetic information and restore vision | Nature
Experimental method to study macula degeneration, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $886 | 275.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 56368671 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125986200 | 26 |
View Market Depth
| Last trade - 11.34am 30/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |